Covered recipient · General Payments record
ALEC S GOLDENBERG
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$2,578.80
- Reported across 117 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,204.78 | 51 |
| Education | $16.53 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $120.79 | 3 |
| Celgene Corporation | $110.27 | 5 |
| Lilly USA, LLC | $95.23 | 4 |
| Ipsen Biopharmaceuticals, Inc | $76.19 | 3 |
| Janssen Biotech, Inc. | $75.38 | 3 |
| PFIZER INC. | $70.59 | 3 |
| Acrotech Biopharma Inc. | $67.37 | 3 |
| Tempus AI, Inc | $65.75 | 3 |
| Alexion Pharmaceuticals, Inc. | $51.29 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $41.45 | 2 |
| GlaxoSmithKline, LLC. | $40.64 | 2 |
| Agios Pharmaceuticals, Inc. | $39.31 | 2 |
| Alnylam Pharmaceuticals Inc. | $34.79 | 1 |
| Mirati Therapeutics, Inc. | $29.86 | 1 |
| TAIHO ONCOLOGY, INC. | $28.17 | 1 |
| EMD Serono, Inc. | $25.67 | 1 |
| Kyowa Kirin, Inc. | $24.99 | 1 |
| Kite Pharma, Inc. | $23.81 | 1 |
| EISAI INC. | $21.49 | 1 |
| ARRAY BIOPHARMA INC | $21.09 | 1 |
| Octapharma USA, Inc. | $20.96 | 1 |
| ABBVIE INC. | $20.95 | 1 |
| Azurity Pharmaceuticals, Inc. | $20.31 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $20.08 | 1 |
| E.R. Squibb & Sons, L.L.C. | $19.40 | 1 |
| Astellas Pharma US Inc | $19.35 | 1 |
| Merck Sharp & Dohme Corporation | $18.70 | 1 |
| Gilead Sciences, Inc. | $17.43 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (52)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.